Advanced Cervical Cancer Clinical Trial
Official title:
Combination of Paclitaxel, Cisplatin\Carboplatin With Toripalimab and Anlotinib for First Line Treatment of Advanced Cervical Cancer
This is a single center phase 1 trail to observe safety and efficacy of Paclitaxel plus Cisplatin\Carboplatin, PD-L1 antibody Toripalimab and Anlotinib as first-line regimen to treat the patient with metastatic 、persistent or recurrent disease after radical surgery、radical platinum-based concurrent chemoradiotherapy or both (Stage IA-IVA).
Advanced cervical cancer patients with metastatic, persistent or recurrent disease after radical surgery、radical platinum-based concurrent chemoradiotherapy or both will be treated by Paclitaxel plus Cisplatin\Carboplatin, PD-L1 antibody Toripalimab and Anlotinib. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01088347 -
Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05068921 -
A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy
|
Phase 1 | |
| Completed |
NCT04590599 -
A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
|
Phase 2 | |
| Terminated |
NCT02853604 -
Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer
|
Phase 3 | |
| Recruiting |
NCT04508686 -
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
|
Phase 1 | |
| Completed |
NCT02888717 -
Molecular Biology Analysis for Para-aortic Nodes in the Ultra-staging of Advanced Cervical Cancers
|
N/A |